TSLX reported Q1 2025 adjusted net investment income of $0.58 per share (13.5% annualized ROE) and adjusted net income of $0.36 per share (8.3% annualized ROE), with forward earnings power estimated at ~$0.50 per share per quarter and reaffirmed full-year ROE guidance of 11.5% to 12.5%.
The portfolio remains high quality, with non-accruals at 1.2% of fair value, a weighted average yield on debt and income-producing securities of 12.3%, and 93% first lien exposure; no new non-accruals were added in Q1.
Q1 saw $154M in new commitments and $137M in fundings, but $270M in repayments led to a net portfolio decrease; repayment activity was elevated, contributing to higher activity-based fee income, notably from a prepayment fee on Arrowhead Pharmaceuticals.
The balance sheet is strong, with $1B in unfunded revolver capacity, no near-term debt maturities (next in August 2026), and a debt-to-equity ratio of 1.15x; recent capital markets activity included a $300M five-year note issuance and an extension/amendment of the revolving credit facility.
The board declared a base quarterly dividend of $0.46 per share and a supplemental dividend of $0.06 per share; management remains disciplined on capital allocation, sees limited direct tariff risk, and expects volatility to create attractive investment opportunities, especially in complex, non-sponsor deals.